X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA LUPIN LTD PLETHICO PHARMA/
LUPIN LTD
 
P/E (TTM) x -1.1 19.9 - View Chart
P/BV x 0.0 2.7 0.6% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 PLETHICO PHARMA   LUPIN LTD
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
LUPIN LTD
Mar-17
PLETHICO PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs3951,750 22.6%   
Low Rs311,384 2.3%   
Sales per share (Unadj.) Rs604.4387.4 156.0%  
Earnings per share (Unadj.) Rs32.556.6 57.3%  
Cash flow per share (Unadj.) Rs51.376.8 66.8%  
Dividends per share (Unadj.) Rs07.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs473.6298.9 158.4%  
Shares outstanding (eoy) m34.08451.58 7.5%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x0.44.0 8.7%   
Avg P/E ratio x6.627.7 23.7%  
P/CF ratio (eoy) x4.220.4 20.4%  
Price / Book Value ratio x0.55.2 8.6%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m7,262707,513 1.0%   
No. of employees `000NA16.8 0.0%   
Total wages/salary Rs m1,59628,495 5.6%   
Avg. sales/employee Rs ThNM10,418.3-  
Avg. wages/employee Rs ThNM1,697.0-  
Avg. net profit/employee Rs ThNM1,523.0-  
INCOME DATA
Net Sales Rs m20,598174,943 11.8%  
Other income Rs m3861,065 36.3%   
Total revenues Rs m20,984176,008 11.9%   
Gross profit Rs m2,81844,931 6.3%  
Depreciation Rs m6429,122 7.0%   
Interest Rs m1,5931,525 104.5%   
Profit before tax Rs m96935,349 2.7%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1389,785 -1.4%   
Profit after tax Rs m1,10725,575 4.3%  
Gross profit margin %13.725.7 53.3%  
Effective tax rate %-14.327.7 -51.6%   
Net profit margin %5.414.6 36.8%  
BALANCE SHEET DATA
Current assets Rs m18,877119,542 15.8%   
Current liabilities Rs m11,89661,206 19.4%   
Net working cap to sales %33.933.3 101.6%  
Current ratio x1.62.0 81.2%  
Inventory Days Days3676 47.3%  
Debtors Days Days19890 220.1%  
Net fixed assets Rs m9,861131,660 7.5%   
Share capital Rs m341903 37.7%   
"Free" reserves Rs m12,331134,073 9.2%   
Net worth Rs m16,139134,976 12.0%   
Long term debt Rs m4,70656,478 8.3%   
Total assets Rs m33,146266,073 12.5%  
Interest coverage x1.624.2 6.7%   
Debt to equity ratio x0.30.4 69.7%  
Sales to assets ratio x0.60.7 94.5%   
Return on assets %8.110.2 80.0%  
Return on equity %6.918.9 36.2%  
Return on capital %12.319.3 63.8%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40281,885 5.4%   
Fx outflow Rs m3,18421,506 14.8%   
Net fx Rs m1,21960,378 2.0%   
CASH FLOW
From Operations Rs m2,43741,148 5.9%  
From Investments Rs m-6,265-25,287 24.8%  
From Financial Activity Rs m2,4904,332 57.5%  
Net Cashflow Rs m-1,33720,193 -6.6%  

Share Holding

Indian Promoters % 82.7 46.6 177.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 4.3 11.3 38.1%  
FIIs % 5.5 31.9 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 10.1 74.3%  
Shareholders   10,665 98,259 10.9%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  GSK PHARMA  FRESENIUS KABI ONCO.  

Compare PLETHICO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS